NCT05190094 - Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions

Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer

Interventions

DRUG

Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)

A combination of Palbociclib (125 mg daily per os (3 weeks on-1 week off) with dose adaptation according to safety profile) and non-steroidal aromatase inhibitor (Letrozole (2.5mg ) or Anastrozole (1mg) daily per os).

Trial Locations (7)

Unknown

NOT_YET_RECRUITING

EHS LCC Blida, Medical Oncology Center, Blida

NOT_YET_RECRUITING

University Hospital Sétif,, Sétif

RECRUITING

King Hussein Cancer Center (KHCC) - Amman, Amman

NOT_YET_RECRUITING

King Saud Medical City - KSMC, Riyadh

NOT_YET_RECRUITING

Medical Oncology Center- King Saud University Medical City (KSUMC), Riyadh

NOT_YET_RECRUITING

Medical Oncology Department- King Fahad Medical City (KFMC), Riyadh

NOT_YET_RECRUITING

Oncology Center Department, King Faisal Specialist Hospital and Research Centre -KFSH & RC, Riyadh

All Listed Sponsors

collaborator

King Saud Medical City

OTHER_GOV

collaborator

Max-Planck-Institut für Quantenoptik (MPQ), and Faculty of Physics at Ludwig-Maximilians-Universität München (LMU), Garching, Germany

UNKNOWN

collaborator

King Abdallah University for Science and Technology (KAUST), Thuwal, Saudi Arabia.

UNKNOWN

lead

International Cancer Research Group, United Arab Emirates

OTHER